National Healthcare Security Administration

73 data points extracted from 6 publications by this organisation.

Data points
73
Documents
6
Indicators
67
Regions
1
Publisher type
Government

Bibliography

Documents used

Every publication we have taken a number from, with the date we read it and the link status at that time.

Every figure

Data points

Every figure taken from this organisation, grouped by indicator.

73 data points across 67 indicators.
IndicatorRegionPeriodValueTypeFull record
Approved Class 1 innovative drugsChina202576actual
Approved Class 1 innovative drugs (half year)Chinaas of 30 Jun 202638actual
Approved drug marketing registration applications (half year)Chinaas of 30 Jun 20262,318actual
Approved innovative drugs with new targets or mechanismsChina202511actual
Approved innovative drugs with new targets or mechanisms (half year)Chinaas of 30 Jun 202611actual
Beneficiaries of negotiated reimbursement drugsChinaas of 31 Oct 2024830 millionactual
Bioequivalence trialsChina20252,218actual
Bioequivalence trials shareChina202542.5%actual
Category 1 innovative drugs added to national health insurance catalogChina202550actual
Centralized procurement drugs added to national reimbursement drug listChinaas of 28 Nov 20242actual
Class 1 innovative drug clinical trialsChina20252,171actual
Class 1 innovative drug clinical trials growth rateChina20254.1%actual
Class 1 innovative drug clinical trials shareChina202572.4%actual
Clinical trial registrationsChina20255,215actual
Clinical trial registrations growth rateChina20256.4%actual
Cumulative drugs added via negotiation in reimbursement drug listChinaas of 28 Nov 2024530actual
Cumulative drugs removed from reimbursement drug listChinaas of 28 Nov 2024438actual
Cumulative newly added drugs in reimbursement drug listChinaas of 28 Nov 2024835actual
Cumulative patient burden reduction from negotiated drugsChinaas of 31 Oct 2024880 billion CNYactual
Domestic first-in-class drug approvalsChina20254actual
Domestic innovative biological product approvalsChina202521actual
Domestic innovative chemical drug approvalsChina202538actual
Domestic share of approved innovative biological productsChina202591.3%actual
Domestic share of approved innovative chemical drugsChina202580.8%actual
Drug clinical trialsChina20255,000actual
Drugs in commercial health insurance innovative drug catalog (annual)China202519actual
Drugs removed from national reimbursement drug listChina202529actual
Drugs removed from national reimbursement drug list (year to date)Chinaas of 28 Nov 202443actual
First-in-class drug approvalsChina202511actual
Imported innovative biological product approvalsChina20252actual
Imported innovative chemical drug approvalsChina20259actual
Innovative biological product approvalsChina202523actual
Innovative biological product approvals (half year)Chinaas of 30 Jun 202617actual
Innovative chemical drug approvalsChina202547actual
Innovative chemical drug approvals (half year)Chinaas of 30 Jun 202620actual
Innovative drug approvalsChina202576actual
Innovative drug approvalsChina202448actual
Innovative drug approvals (year to date)Chinaas of 15 Apr 202614actual
Innovative drug out-licensing deal countChina2025150actual
Innovative drug out-licensing deal countChina202494actual
Innovative drug out-licensing deal count (half year)Chinaas of 30 Jun 202681actual
Innovative drug out-licensing deal valueChina2025130 billion USDactual
Innovative drug out-licensing deal valueChina2025130 billion USDactual
Innovative drug out-licensing deal valueChina202451.9 billion USDactual
Innovative drug out-licensing deal value (half year)Chinaas of 30 Jun 2026110 billion USDactual
Innovative traditional medicine approvalsChina20256actual
Innovative traditional medicine approvals (half year)Chinaas of 30 Jun 20261actual
International multi-center clinical trialsChina2025410actual
International multi-center clinical trials shareChina202513.7%actual
Negotiated or bid drugs added to national reimbursement drug listChinaas of 28 Nov 202489actual
Negotiated pharmaceutical sales driven by medical insuranceChinaas of 28 Feb 2026740 billion CNYactual
New drug approvalsChina2025248actual
New drug clinical trial initiation time reductionChina20254 monthsactual
New drug clinical trialsChina20252,997actual
New drug clinical trialsChina20252,997actual
New drug clinical trials growth rateChina202518%actual
New drug clinical trials shareChina202557.5%actual
New drug clinical trials shareChina202557.5%actual
Newly added drugs in national reimbursement drug listChinaas of 28 Nov 202491actual
Newly added drugs in national reimbursement drug list (annual)China2025114actual
Off-catalog drugs participating in price negotiation or biddingChinaas of 28 Nov 2024117actual
Pharmaceutical industry R&D expenditure growth rateChina2021–202523%actual
Pharmaceutical industry total profit growth rateChina2021–202511.3%actual
Radiopharmaceutical market sizeChina203026 billion CNYforecast
Reimbursement drug list conventional medicinesChinaas of 28 Nov 20241,765actual
Reimbursement drug list conventional medicines (annual)China20251,857actual
Reimbursement drug list total drugsChinaas of 28 Nov 20243,159actual
Reimbursement drug list total drugs (annual)China20253,253actual
Reimbursement drug list traditional patent medicinesChinaas of 28 Nov 20241,394actual
Reimbursement drug list traditional patent medicines (annual)China20251,396actual
Share of global biopharmaceutical pipeline (snapshot)Chinaas of 30 Jun 202630%actual
Successful price negotiations or bids for off-catalog drugsChinaas of 28 Nov 202489actual
Top 50 global pharmaceutical companies countChinaas of 15 Apr 20266actual

Cite & reuse

Cite this page

Data on this page is published under CC BY 4.0. Credit National Healthcare Security Administration as the original publisher; each record page carries its own citation.

National Healthcare Security Administration. Retrieved from StatOrigin: https://statorigin.org/sources/national-healthcare-security-administration

Keep exploring

Related

Last verified 17 September 2026. Link status is rechecked weekly.